LEO Pharma’s new R&D lead on driving agility in drug developmentAfter 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research Share XLEO Pharma’s new R&D lead on driving agility in drug developmenthttps://deep-dive.pharmaphorum.com/magazine/research-and-development-2021/leo-pharma-rd-lead-agility-drug-development/
Deep Dive: Research and DevelopmentPharma’s historic R&D efforts have given us some light at the end of the COVID tunnel. Now it’s Share XDeep Dive: Research and Developmenthttps://pharmaphorum.com/r-d/views-analysis-r-d/deep-dive-research-and-development/
Gitte Aabo on telemedicine and GN Hearing: the pharmaphorum podcastJoining the pharmaphorum podcast for episode 24 is Gitte Aabo, who last year moved to hearing aid technology Share XGitte Aabo on telemedicine and GN Hearing: the pharmaphorum podcasthttps://pharmaphorum.com/podcast/gitte-aabo-telemedicine-gn-hearing
LEO eyeing 2021 US launch for eczema drug tralokinumabLEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the Share XLEO eyeing 2021 US launch for eczema drug tralokinumabhttps://pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/
Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUThe EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic Share XEyeing Dupixent’s territory, Leo Pharma files tralokinumab in EUhttps://pharmaphorum.com/news/eyeing-dupixents-territory-leo-pharma-files-tralokinumab-in-eu/
Towards Patient Centricity: LEO PharmaIndustry plays a pivotal role in making sure patient needs are not overlooked by the wider healthcare community. Share XTowards Patient Centricity: LEO Pharmahttps://pharmaphorum.com/views-analysis-patients/towards-patient-centricity-leo-pharma/
Smartphone app provides skin cancer early warning serviceThe makers of a smartphone app are hoping that it could be used to play a crucial role Share XSmartphone app provides skin cancer early warning servicehttps://pharmaphorum.com/news/smartphone-app-provides-skin-cancer-early-warning-service/
Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Deep Dive: Access and CommercialisationIn this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing Share XDeep Dive: Access and Commercialisationhttps://pharmaphorum.com/digital/pharma-access-commercialisation/
